机器人时代开放与机器人辅助单纯前列腺切除术的围手术期结局与费用比较
基于美国全国住院患者样本(NIS)2013–2016年数据,比较开放单纯前列腺切除术(OSP,n=2551)与机器人辅助单纯前列腺切除术(RASP,n=704)的围手术期结局和住院费用。多变量回归显示机器人入路额外增加6175美元(P<0.01),每增加1天住院增加1687美元(P<0.01)。
要点
- RASP总并发症率显著低于OSP(11.1% vs 29.2%,P<0.01)。
- RASP住院时间更短(中位2天 vs 4天,P<0.01)且出院回家比例更高。
- RASP未调整住院费用更高,机器人入路额外贡献6175美元(P<0.01)。
核心结论
- RASP围手术期并发症率更低、住院时间更短且更可能出院回家,但总住院费用仍高于OSP,可能与机器人 upfront 手术成本相关。
- 在经验丰富的盆腔机器人中心,RASP的康复优势、出院回家率和更低并发症率可为其较高住院费用提供依据,尤其当转诊至经验丰富的钬激光前列腺剜除中心不可行时。
研究设计与样本
- 回顾性比较分析,查询美国全国住院患者样本(NIS)2013–2016年因BPH行OSP或RASP的病例。
- 分析队列共2551例OSP和704例RASP。
- 比较围手术期并发症、未调整住院费用和住院时间(LOS),采用平滑线性回归和多元线性回归构建费用模型。
主要发现
- RASP患者更年轻,中位年龄68(IQR 63–73)岁 vs OSP 71(IQR 65–77)岁。
- RASP患者合并症更少(76.8% vs 86.5%,P<0.01)。
- RASP总并发症更少(11.1% vs 29.2%,P<0.01),常规出院回家比例更高(88.9% vs 76.7%,P<0.01)。
- RASP住院时间更短(中位2[IQR 1–3]天 vs 4[IQR 3–6]天,P<0.01)。
关键数值与推荐
- RASP住院中位2天与OSP住院5–6天时费用等效。
- 多变量回归中机器人入路额外增加6175美元(P<0.01),每额外住院1天增加1687美元(P<0.01)。
- RASP需缩短住院3–4天才能抵消机器人手术成本。
- 出现任何并发症均增加住院时间和住院费用(P<0.01)。
临床怎么用
- 在经验丰富的盆腔机器人中心,RASP可提供更低的围手术期并发症率、更短住院时间和更高的出院回家率,但费用较高。
- 若无法转诊至经验丰富的钬激光前列腺剜除中心,RASP的康复优势可为其较高住院费用提供依据。
- 并发症发生会同时增加住院时间和费用,应重视围手术期并发症防控。
局限性
- 回顾性研究,RASP患者存在选择偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To perform a comparative analysis of perioperative outcomes and hospitalisation cost between open (OSP) and robot-assisted simple prostatectomy (RASP) for treatment of benign prostatic hyperplasia (BPH) using the National Inpatient Sample (NIS) in the contemporary robotic era. MATERIALS AND METHODS: The NIS was queried for cases of OSP and RASP for the treatment of BPH between 2013 and 2016. Perioperative complications, unadjusted hospital cost and length of stay (LOS) were compared between RASP and OSP. Smoothed linear regression curves comparing hospitalisation cost by increasing LOS was stratified by surgical approach to identify point of cost equivalency between RASP and OSP. Multivariable linear regression analysis was used to construct a hospitalisation cost model to examine the contribution of the robotic approach and LOS to hospitalisation cost. RESULTS: The total analytical cohort included 2551 OSP and 704 RASP procedures. Patients undergoing RASP were younger, at a median (interquartile range [IQR]) age of 68 (63-73) vs 71 (65-77) years, and with less comorbidity (76.8% vs 86.5%, P < 0.01). RASP was associated with fewer total complications (11.1% vs 29.2%, P < 0.01) and a greater likelihood of routine discharge to home rather than another facility (88.9% vs 76.7%, P < 0.01). While LOS was shorter with RASP (median [IQR], 2 [1-3] vs 4 [3-6] days, P < 0.01), total unadjusted hospitalisation cost (in United States dollars) was greater (median [IQR], $10 855 [$7965-$15 675] vs $13 467 [$10 572-$17 722], P < 0.01). Presence of any complication increased both LOS and hospitalisation cost (P < 0.01). Linear regression modelling determined the point of cost equivalence between RASP staying a median of 2 days was an OSP case staying between 5 and 6 days. On multivariable regression analysis, the robotic approach contributed an additional $6175 (P < 0.01) to the cost model, whereas each additional day of hospitalisation contributed $1687 (P < 0.01), suggesting LOS would need to be 3-4 days shorter with RASP to offset surgical costs of the robot. CONCLUSIONS: While RASP appears to have significantly better perioperative complication rates with shorter LOS and likely discharge to home, total hospitalisation cost remained greater, likely related to upfront operative costs. While this retrospective study is limited by selection bias for patients undergoing RASP, the benefits of improved convalescence, discharge to home, and lower rate of perioperative complications appear to justify performance of RASP in an experienced pelvic robotic centre despite relatively greater hospitalisation cost if referral to an experienced holmium laser enucleation of the prostate centre is not feasible.
引用
- Bhanvadia R, Ashbrook C, Gahan J, et al. Perioperative outcomes and cost of robotic vs open simple prostatectomy in the modern robotic era: results from the National Inpatient Sample. BJU Int. 2020. PMID: 32981194. doi:10.1111/bju.15258
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。